Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Danny Rayes"'
Autor:
Sarah E. Mudra, MD, Danny Rayes, MD, Ashwin K. Kumar, MD, Jason Z. Li, MD, Meredith Njus, MD, Kevin McGowan, MD, Charalampos Charalampous, MD, Kazi A. Kalam, MSc, Alveena Syed, MD, Muhammad Majid, MD, Mary Schleicher, RN, BSN, MLIS, Ankit Agrawal, MD, Abdullah Yesilyaprak, MD, Allan L. Klein, MD
Publikováno v:
CJC Open, Vol 6, Iss 8, Pp 967-972 (2024)
Background: Malignant pericardial effusion (Eff) is often asymptomatic and has an unknown prevalence, due to its occult presentation. The condition often is identified postmortem on autopsy, and it is associated with a poor prognosis. Given the late
Externí odkaz:
https://doaj.org/article/b9560ffe375744cda1506d8ec596d47e
Autor:
Aditya Dewanjee, Danny Rayes, Moemen Eltelbany, Jamie Kennedy, Anika Raja, Behnam Nonahal Tehrani, Palak Shah, Shashank Desai, Edward William Howard, Daniel Giunway Tang, Ramesh Singh, Christopher King, Hala Moukhachen, Mitchell Psotka, Karl D. Young, Shashank S. Sinha, Raghav Gattani
Publikováno v:
Journal of the American College of Cardiology. 81:3196
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdf3f05a9fcca97f83e68d7acead605c
https://doi.org/10.1016/s0735-1097(23)03640-9
https://doi.org/10.1016/s0735-1097(23)03640-9
Autor:
Ethan Sokol, Raymond C. Wadlow, Timothy L. Cannon, Halla Nimeiri, Jamie Randall, John F. Deeken, Sonja Alexander, Daniel Barnett, Danny Rayes, Kimberly McGregor
Publikováno v:
Journal of Clinical Oncology. 39:3561-3561
3561 Background: BRAF V600E+, MSS mCRC patients comprise up to 10% of advanced CRC. They have a poor prognosis with median survivals typically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6535dc83a941fd2efab912f031e97e0f
https://doi.org/10.1200/jco.2021.39.15_suppl.3561
https://doi.org/10.1200/jco.2021.39.15_suppl.3561
Autor:
Dan Barnett, Jamie Randall, Sarah Mullaly, Gail Payne, Erica Marchlik, Sheryl Krevsky Elkin, Danny Rayes, Hongkun Wang, Raymond C. Wadlow, Lindsey Tishman, Timothy L. Cannon
Publikováno v:
Journal of Clinical Oncology. 39:129-129
129 Background: KRAS and NRAS (RAS) mutations are considered driver mutations in gastrointestinal malignancies such as colorectal and pancreatic cancer. Our institution obtains broad molecular testing (commercial panels with full exon coverage of at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9efe756b61a0ee4206ca4ad621b3b26b
https://doi.org/10.1200/jco.2021.39.3_suppl.129
https://doi.org/10.1200/jco.2021.39.3_suppl.129